NCT03682848View on ClinicalTrials.gov

Safety and Efficacy of Dolutegravir/Lamivudine (DTG/3TC) in Therapy-naive Human Immunodeficiency Virus-1 (HIV-1) Infected Adolescents

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

April 9, 2019

Primary Completion Date

December 1, 2021

Study Completion Date

September 30, 2024

Conditions
HIV Infections
Interventions
DRUG

DTG + 3TC FDC

DTG + 3TC FDC will be available as 50/300 milligrams tablet to be given orally once daily.

Trial Locations (8)

2013

GSK Investigational Site, Soweto

4052

GSK Investigational Site, Durban

7505

GSK Investigational Site, Tygerberg

10330

GSK Investigational Site, Bangkok

10700

GSK Investigational Site, Bangkok

20200

GSK Investigational Site, Kericho

40100

GSK Investigational Site, Kisumu

50200

GSK Investigational Site, Chiang Mai

Sponsors

Lead Sponsor

ViiV Healthcare
All Listed Sponsors
lead

ViiV Healthcare

INDUSTRY